about
Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strengthCloning of a novel membrane-linked metalloproteinase from human myeloma cellsOsteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.Rapid phenotyping of knockout mice to identify genetic determinants of bone strengthExpression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytesA mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosisTargeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivoA mouse model of early-onset renal failure due to a xanthine dehydrogenase nonsense mutationN-ethyl-N-Nitrosourea (ENU) induced mutations within the klotho gene lead to ectopic calcification and reduced lifespan in mouse modelsMice with an N-Ethyl-N-Nitrosourea (ENU) Induced Tyr209Asn Mutation in Natriuretic Peptide Receptor 3 (NPR3) Provide a Model for Kyphosis Associated with Activation of the MAPK Signaling PathwayNext generation mapping reveals novel large genomic rearrangements in prostate cancerZoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivoInhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaThyroid hormone receptor α mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excessMetastasis and bone loss: advancing treatment and prevention.Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancerThe Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21WAF1/CIP1 in 143B Osteosarcoma Cell Growth Arrest.Evidence of a role for RANKL in the development of myeloma bone disease.Prader-Willi Critical Region, a Non-Translated, Imprinted Central Regulator of Bone Mass: Possible Role in Skeletal Abnormalities in Prader-Willi Syndrome.Thyrostimulin Regulates Osteoblastic Bone Formation During Early Skeletal Development.The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancerMyeloma bone disease and proteasome inhibition therapies.Signaling between tumor cells and the host bone marrow microenvironment.Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies.The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.Bone metastasis: the importance of the neighbourhood.Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage.Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis.Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.Bone Mineral Content and Density.Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.Melphalan modifies the bone microenvironment by enhancing osteoclast formation.The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.
P50
Q21563368-F0ECCE16-E253-4AB4-8979-DFCB901F024EQ24529902-945A2205-F656-42D5-AFC6-EC18DBB64F3DQ27316833-8DEA567B-2D2E-4A46-A693-3B4157D37AFAQ28066355-82745C6F-66A5-40D0-AA72-4E7E22D40468Q28302629-BE9B31F9-3378-4183-9940-FBFFC30D109AQ28482201-86DC2F82-E433-4969-A33C-E956D099EABCQ28483760-F36A3299-EC05-49BF-853B-35FDC7868F34Q28483790-A23F7AC8-0659-4492-B402-B9FC12433B03Q28546036-FBE8E634-7498-49C1-958B-D40F7E165CB1Q28555004-738CA384-B072-4638-A5E8-12A4BA094F25Q33618785-0D148B44-31C1-44FC-8C93-833DB53A8213Q33692900-89BB7798-76B7-40B9-BB2F-293A3D32FC07Q33856318-4993A424-35AA-41E4-BA05-4031F3D68638Q34068384-260E8695-86E3-41E3-BC5C-BD25245FEC60Q34316496-4731D047-D6E9-4626-AA56-91190346001CQ34617837-739B01F0-0D72-461B-923C-CC372039FFE7Q34945422-F09CCBA8-8CE5-4E44-997E-7FF9949FF1D0Q35649604-296F7810-514F-470C-B3A4-EB92461517C5Q35834894-CF7BC4AC-8BE7-44C9-8A18-54EAFBCEA7F4Q35908156-F4FADA3C-CB63-4AE9-BD21-1F0196C439AFQ35970871-E9E9E34D-DC00-46E1-B780-FC577851FAA2Q36190094-9B4815A4-75E4-4C93-B876-938A8802CE74Q36818075-04FEA386-C15E-4933-8069-E02EC9B8CBCBQ38138849-386B7039-747C-470D-B1CE-BB1B0106C238Q38344895-0D799105-999C-413F-8B88-851B0D3395CAQ38810794-A1B496FD-7DAF-4265-8E6D-122B80D2BC8EQ38843253-297E4D64-0EE3-4B4F-81CB-DDBEE692E13DQ38972676-056DF5B1-5811-4065-A1A2-E6A3D3E8CEBBQ38981998-64959464-2A0F-4481-B9AE-DA9B2EB014BEQ39645403-70C87E26-1AFA-415B-A630-0BDF692F42BDQ39915275-1DAB84FF-3AAC-49B1-9A80-52AA2EB990FCQ40059056-9CBD057F-9C75-42F1-9D73-25E1A4860BEDQ40108030-0C27E2BD-1E83-4C02-86C7-7F5F11F87D70Q40168303-C8FC2FD6-EE73-4F0D-A5ED-3DC83051A3C4Q40287894-0383FA67-4CD6-4816-893C-760A6FEF6962Q40742643-91D49E32-A2E3-4F5C-B98E-EEFB28A53BEDQ41087450-E3A3917D-829D-4095-91F8-404DD9878521Q41555770-714F7AFB-22FA-41DE-9508-1F17CB486C06Q42366597-45A2B3DE-659F-4A0D-881D-3F60815563FCQ43442169-964F70DD-4783-402A-B964-683B1529842B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter I Croucher
@ast
Peter I Croucher
@en
Peter I Croucher
@es
Peter I Croucher
@nl
type
label
Peter I Croucher
@ast
Peter I Croucher
@en
Peter I Croucher
@es
Peter I Croucher
@nl
prefLabel
Peter I Croucher
@ast
Peter I Croucher
@en
Peter I Croucher
@es
Peter I Croucher
@nl
P106
P31
P496
0000-0002-7102-2413